BCR and B-cell chronic lymphocytic leukemia: In a subsequent phase 1b/2 study, 61 patients with relapsed or refractory CLL were enrolled at 2 different doses (420 mg and 840 mg).98 As seen with other BCR inhibitors, a characteristic pattern of response occurred in the majority of patients, with an initial transient increase in lymphocytosis that diminished over time.